Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
- 13 April 2011
- journal article
- review article
- Published by Wiley in Immunological Reviews
- Vol. 241 (1), 104-118
- https://doi.org/10.1111/j.1600-065x.2011.01007.x
Abstract
Summary: The continual interaction of the immune system with a developing tumor is thought to result in the establishment of a dynamic state of equilibrium. This equilibrium depends on the balance between effector and regulatory T‐cell compartments. Whereas regulatory T cells can infiltrate and accumulate within tumors, effector T cells fail to efficiently do so. Furthermore, effector T cells that do infiltrate the tumor become tightly controlled by different regulatory cellular subsets and inhibitory molecules. The outcome of this balance is critical to survival, and whereas in some cases the equilibrium can rapidly result in the elimination of the transformed cells by the immune system, in many other cases the tumor manages to escape immune control. In this review, we discuss relevant work focusing on the establishment of the intratumor balance, the dynamic changes in the populations of effector and regulatory T cells within the tumor, and the role of the tumor vasculature and its activation state in the recruitment of different T‐cell subsets. Finally, we also discuss work associated to the manipulation of the immune response to tumors and its impact on the infiltration, accumulation, and function of tumor‐reactive lymphocytes within the tumor microenvironment.Keywords
This publication has 210 references indexed in Scilit:
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Intraepithelial Effector (CD3+)/Regulatory (FoxP3+) T-Cell Ratio Predicts a Clinical Outcome of Human Colon CarcinomaGastroenterology, 2009
- Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivoNature Immunology, 2009
- Central Role of Defective Interleukin-2 Production in the Triggering of Islet Autoimmune DestructionImmunity, 2008
- Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapyCancer Immunology, Immunotherapy, 2008
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell ResponsesImmunity, 2007
- Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancerNature Medicine, 2007
- Foxp3 in control of the regulatory T cell lineageNature Immunology, 2007
- CD4+ T Cells Cooperate With Macrophages for Specific Elimination of MHC Class II-Negative Cancer CellsAdvances in experimental medicine and biology, 2007
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002